The Quality of Registration of Clinical Trials

Viergever, Roderik F.; Ghersi, Davina
February 2011
PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1
Academic Journal
Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous evaluations of registered records of clinical trials have shown that registered information is often incomplete and non-meaningful. If these studies are accurate, this negates the possible benefits of registration of clinical trials. Methods and Findings: A 5% sample of records of clinical trials that were registered between 17 June 2008 and 17 June 2009 was taken from the International Clinical Trials Registry Platform (ICTRP) database and assessed for the presence of contact information, the presence of intervention specifics in drug trials and the quality of primary and secondary outcome reporting. 731 records were included. More than half of the records were registered after recruitment of the first participant. The name of a contact person was available in 94.4% of records from non-industry funded trials and 53.7% of records from industry funded trials. Either an email address or a phone number was present in 76.5% of non-industry funded trial records and in 56.5% of industry funded trial records. Although a drug name or company serial number was almost always provided, other drug intervention specifics were often omitted from registration. Of 3643 reported outcomes, 34.9% were specific measures with a meaningful time frame. Conclusions: Clinical trials registration has the potential to contribute substantially to improving clinical trial transparency and reducing publication bias and selective reporting. These potential benefits are currently undermined by deficiencies in the provision of information in key areas of registered records.


Related Articles

  • Trial results: the next battle. Abbasi, Kamran // BMJ: British Medical Journal (International Edition);1/15/2005, Vol. 330 Issue 7483, precedes p. 103 p103 

    Presents comments on an announcement by drug companies that results of clinical trials for drugs may soon become available to the public. Concerns about prescription drugs and their possible harmful effects; Assertion that unless the proposal to release clinical trial results is mandatory it...

  • Calendar of Events.  // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p104 

    This article presents information on various events related to clinical trials to be held in several countries. Conference on Project Management for Clinical Trials will be held in Irvine, California on June 1-2, 2004. Conference titled "Monitoring Clinical Drug Studies: Beginner," will be held...

  • Patient study explores trial results question.  // European Pharmaceutical Executive;May/Jun2006, p14 

    The article reports that Taxotere as Adjuvant ChemoTherapy (TACT) has explored the question of if and how patients should be told of the results of clinical trials in which they participate. TACT's study revealed that posting results directly to patients' homes was preferred and that most of the...

  • Experts emphasize need for speed in launch of Australian trials. Morgan, Branwen // Nature Medicine;May2011, Vol. 17 Issue 5, p521 

    The article reports on the need for a faster launch in conducting clinical trials of drugs in Australia. It mentions that the number of new trials recorded in the country has decreased to 574 due to higher operating costs and competition from the emerging countries. To address the issue, it...

  • Novartis to begin ADHD study in girls.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p12 

    Reports on the commencement of a new clinical study to evaluate the efficacy and safety of Ritalin LA extended release capsules in girls aged 12 to 17 years old with attention-deficit/hyperactivity disorder (ADHD). Study design; Objective of the study; Potential impact of the study in the...

  • DOV shows positive phase III results for bicifadine.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p14 

    Presents results of a phase III clinical trial of non-narcotic analgesic bicifadine. Indication of bicifadine; Efficacy of bicifadine as an analgesic; Demonstration of the analgesic effects of bicifadine in a well accepted clinical pain procedure.

  • Why are clinical costs so high? Frantz, Simon // Nature Reviews Drug Discovery;Nov2003, Vol. 2 Issue 11, p851 

    Discusses the rise in the costs of clinical development in the U.S. Large increase in the cost of clinical development compared to preclinical costs which has made them the most expensive aspect of drug development; Suggestion of Joseph DiMasi, Director of Economic Analysis at the Tufts Center...

  • How Evident is Evidence? Traverso, Silvano // Biology Forum / Rivista di Biologia;2009, Vol. 102 Issue 2, p153 

    This article comments on the practice of evidence-based medicine in the U.S. It reflects on a study which reviewed clinical trials on the effectiveness of antidepressants. It criticizes the study for failing to publish trials with negative results. In addition, the article scrutinizes the...

  • news in brief.  // Nature;1/6/2005, Vol. 433 Issue 7021, p6 

    This article reports on developments in scientific research. One of them relates to the clinical trials of blockbuster drugs that have been made public by pharmaceutical company Eli Lilly & Co. The Indianapolis-based firm launched the online Lilly Clinical Trial Registry, which contains trial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics